HANSOH PHARMA (03692.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Event Tracking

Dec16

Glenmark Pharmaceuticals Ltd Secures Exclusive Rights to Aumolertinib from Hansoh Pharmaceutical

10:11

Hansoh Pharmaceutical's Wholly-owned Subsidiary Enters into Exclusive Licensing, Collaboration and Distribution Agreement for Amivantamab with Glenmark

10:04

Dec13

UBS Analyst Maintains Buy Rating on Hansoh Pharmaceutical

01:17

Dec11

Hanson Pharmaceutical Group Reports Strong Phase II Clinical Trial Results for RET Inhibitor Resencatinib

10:09

Dec10

Hanson Pharmaceutical's risvutatug rezetecan shows promising results in Phase 1 trial for NSCLC

09:54

Dec7

Hanson Pharma’s Multiple Drugs Included in the New National Health Insurance Directory

23:08

Schedules & Filings

Schedules

Filings

Oct30

Distribution Plan(CST)

Cash dividend 0.2316 HKD

Sep25

Distribution Plan(CST)

Cash dividend 0.2316 HKD

Sep22

Distribution Plan(CST)

Cash dividend 0.2316 HKD

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change